Bioequivalency Study of 5 mg Piolocarpine Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine
Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fed conditions using a
single-dose, 2-treatment, 2-period, crossover design.